International Biotechnology Trust’s Acceleron Pharma XLRN Stock Holding History

International Biotechnology Trust’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-60,500	Closed	-$7.59M	–	76
2021 Q2	$7.59M	Hold	60,500	–	–	2%	16
2021 Q1	$8.2M	Sell	60,500 -10,500	-15%	-$1.36M	2.17%	17
2020 Q4	$9.06M	Hold	71,000	–	–	2.48%	16
2020 Q3	$7.98M	Buy	71,000 +53,000	+294%	+$5.28M	2.58%	16
2020 Q2	$1.73M	Hold	18,000	–	–	0.57%	29
2020 Q1	$1.62M	Sell	18,000 -39,000	-68%	-$3.03M	0.74%	25
2019 Q4	$3.02M	Buy	57,000 +27,000	+90%	+$1.23M	1.09%	25
2019 Q3	$1.18M	Hold	30,000	–	–	0.55%	36
2019 Q2	$1.23M	Hold	30,000	–	–	0.46%	47
2019 Q1	$1.4M	Buy	+30,000	New	+$1.32M	0.52%	49
2017 Q4	–	Sell	-153,633	Closed	-$5.75M	–	71
2017 Q3	$5.75M	Sell	153,633 -24,010	-14%	-$833K	2.24%	14
2017 Q2	$5.4M	Buy	177,643 +7,037	+4%	+$204K	2.05%	13
2017 Q1	$4.51M	Buy	170,606 +152,000	+817%	+$4.01M	1.73%	17
2016 Q4	$475K	Buy	+18,606	New	+$590K	0.21%	46

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

International Biotechnology Trust's XLRN Position: Q3 2021 in Review

International Biotechnology Trust sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 60,500 shares — an estimated $7.59M sold.

International Biotechnology Trust first reported a position in XLRN in Q4 2016 and held it in 14 quarters. The position peaked at $9.06M in Q4 2020. 331 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

International Biotechnology Trust reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
International Biotechnology Trust sold 60,500 Acceleron Pharma shares in Q3 2021, an estimated $7.59M.
International Biotechnology Trust first reported a position in Acceleron Pharma in Q4 2016 and held it in 14 quarters.
International Biotechnology Trust's Acceleron Pharma position peaked at $9.06M in Q4 2020.
331 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on International Biotechnology Trust's 13F filing for Q3 2021, filed 12 Nov 2021.